Tag: narrow therapeutic index
Jun, 24 2026
Pharmacist Concerns About NTI Generics: Professional Perspectives on Safety and Substitution
Explore why pharmacists are concerned about NTI generic substitutions. Learn about bioequivalence gaps, safety risks, and how professionals manage narrow therapeutic index drugs in 2026.
Jan, 12 2026
Narrow Therapeutic Index Drugs: Why Bioequivalence Rules Are Tighter for These Medications
Narrow therapeutic index drugs require stricter bioequivalence standards because small differences in dosage can cause serious harm. Learn how the FDA, EMA, and Health Canada regulate generics like warfarin, levothyroxine, and digoxin to ensure patient safety.